Trial of Naltrexone and Dextromethorphan for Gulf War Illness

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2016-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Veterans of the 1991 Gulf War who developed Gulf War Illness are being studied. Treatments with FDA approved generic drugs are being administered to see if they help with the symptoms of Gulf War Illness, such as chronic fatigue; difficulty with memory, concentration, and thinking; widespread chronic pain; and autonimic dysfunction. Drugs to be tested are dextromethorphan and naltrexone.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ketamine in Veterans With Gulf War Illness

NCT04712071

Gulf War Syndrome

TERMINATED EARLY_PHASE1

To Investigate the Gastrointestinal Behaviour of Two Triple Combination Products in Healthy Male Volunteers

NCT03415243

Common Cold

COMPLETED PHASE1

Open Label Transdermal Granisetron to Relieve Chronic Nausea and Emesis

NCT04501211

Gastroparesis

WITHDRAWN PHASE2

Ondansetron and the QT Interval In Adult Emergency Department Patients

NCT01759420

Ondansetron

COMPLETED

Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis

NCT02357420

Diabetes Mellitus Diabetes Mellitus Complications Gastroparesis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Gulf war veterans' illnesses comprise distinct clusters of symptom-defined illnesses for which there are neither diagnostic tests nor effective treatments. Gulf war veterans had variable exposures to a number of chemicals, including organophosphate insecticides, pyrethrum-related insecticides, DEET, Pyridostigmine bromide, smoke from oil well fires, and Sarin gas. Gulf war veterans' illnesses may reflect an inflammatory cycle involving the brain which may be a common mechanism of many neurological conditions, whether initiated by toxic exposures, infection, or trauma. In this theory, central nervous system inflammation initiated by toxic exposures and sometimes exacerbated by subsequent exposures is a component of illness hypothesized to explain the neurological manifestations. Substance P release at sensory nerve endings is an explanation for the peripheral pain manifestations of illness.

This theory suggests that novel anti-inflammatory drugs may be of benefit in symptom-defined illnesses related to a cycle of inflammation. Dr. J. S. Hong's laboratory at the National Institute of Environmental Health Sciences has demonstrated that Morphine-related analogs, including Naltrexone and Dextromethorphan, have great potency in anti-inflammation and neuroprotective effects. Naltrexone is a safe and readily available generic medication. Dextromethorphan is also a safe and readily available generic medication that is available without a prescription as a cough medication. Results from several clinical trials showed that Naltrexone is effective in several inflammation-related diseases, such as neurogenic pain, movement disorders, etc. In addition, there were no obvious side effects in patients taking this drug for six months. This project will conduct randomized double-blinded studies for treating ill Gulf war veterans with Naltrexone and Dextromethorphan. Laboratory tests for markers of inflammation including neurogenic inflammation will be performed pre- and post-treatment, to see if these markers are elevated and if so, to see if treatment modulates these markers.

Ill Gulf veterans will be recruited through the media, veterans groups, and individual veteran activists. A screening telephone interview will be performed to determine if the veterans meet a modified Kansas case definition for inclusion. Those veterans who meet study criteria will be invited to participate. Eligible veterans will be invited for an initial visit that will consist of obtaining written informed consent, a medical history, physical examination, and laboratory testing. Institutional review board approval of the study will be in place. The pharmacy staff at the institution will prepare the medications and placebo in identical capsules.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gulf War Illness

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Naltrexone Study Drug

Subjects will take naltrexone 4.5 mg daily for three months.

Group Type ACTIVE_COMPARATOR

naltrexone

Intervention Type DRUG

Randomized controlled trial of naltrexone for Gulf War Illness.

Naltrexone placebo

Subjects will take a 3 month course of a placebo pill identical in appearance to the naltrexone study drug.

Group Type PLACEBO_COMPARATOR

naltrexone

Intervention Type DRUG

Randomized controlled trial of naltrexone for Gulf War Illness.

dextromethrophan study drug

subjects will take a sustained release dextromethorphan pill twice a day.

Group Type ACTIVE_COMPARATOR

Dextromethorphan

Intervention Type DRUG

Randomized controlled trial of dextromethorphan for Gulf War Illness

dextromethoprhan placebo

Subjects will take a 3 month course of a placebo pill identical in appearance to the dextromethorphan study drug.

Group Type PLACEBO_COMPARATOR

Dextromethorphan

Intervention Type DRUG

Randomized controlled trial of dextromethorphan for Gulf War Illness

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

naltrexone

Randomized controlled trial of naltrexone for Gulf War Illness.

Intervention Type DRUG

Dextromethorphan

Randomized controlled trial of dextromethorphan for Gulf War Illness

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Served in the Gulf War and developed the symptoms of Gulf War Illness as described by the modified Kansas Case Definition

Exclusion Criteria

* Pregnant women, nursing mothers, individuals requiring medications that have drug interactions with dextromethorphan or naltrexone, cancer not in remission, chronic infectious disease, liver disease, lupus, multiple sclerosis, stroke, under current treatment for schizophrenia, bipolar disorder/manic depression, and depression.
* Those with a history of current illicit drug use will be excluded. Individuals who have had recent surgery will not be enrolled until they have completely recovered from the surgery.
* Subjects participating in other clinical trials will be excluded.
* Those enrolled recently in a clinical trial will be enrolled after a washout period of one month.

Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No